XML 37 R7.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended 24 Months Ended
Aug. 31, 2025
Aug. 31, 2024
Aug. 31, 2023
Aug. 31, 2024
Cash flows from operating activities        
Net (loss) income $ (64,718,000) $ 9,954,000 $ 9,961,000  
Adjustments to reconcile net income to net cash provided by operating activities        
Depreciation and amortization 8,211,000 5,665,000 3,840,000  
Change in fair value of contingent consideration (640,000) (1,639,000) 680,000  
Discharge of holdback obligation related to Immunetrics acquisition (224,000) 0 0  
Amortization of investment discounts (64,000) (1,116,000) (1,134,000)  
Stock-based compensation 6,354,000 6,538,000 4,828,000  
Deferred income taxes (5,426,000) (1,765,000) (2,095,000)  
Loss from disposal of assets 23,000 0 6,000  
Impairments 77,221,000 0 500,000  
Currency translation adjustments (25,000) (105,000) 167,000  
(Increase) decrease in        
Accounts receivable (581,000) 3,129,000 4,097,000  
Prepaid income taxes 420,000 (1,393,000) 587,000  
Prepaid expenses and other assets 194,000 (2,143,000) (501,000)  
Increase (decrease) in        
Accounts payable (132,000) (477,000) (81,000)  
Other liabilities (3,187,000) (768,000) 832,000  
Accrued income taxes 0 0 (7,000)  
Deferred revenue 700,000 (2,560,000) 176,000  
Net cash provided by operating activities 18,126,000 13,320,000 21,856,000  
Cash flows from investing activities        
Purchases of property and equipment (713,000) (566,000) (453,000)  
Purchase of short-term investments (6,500,000) (67,159,000) (95,045,000)  
Proceeds from maturities of short-term investments 14,017,000 71,089,000 114,907,000  
Proceeds from sales of investments 995,000 45,177,000 0  
Issuance of promissory note (1,000,000) 0 0  
Purchased intangibles (379,000) (541,000) (601,000)  
Business acquisition, net of cash acquired 0 (98,773,000) (8,223,000)  
Net working capital & excess cash settlement - Pro-ficiency acquisition (227,000) 0 0  
Capitalized computer software development costs (2,631,000) (3,194,000) (3,219,000)  
Net cash used in investing activities 3,562,000 (53,967,000) 7,366,000  
Cash flows from financing activities        
Payment of dividends 0 (4,796,000) (4,809,000)  
Payments on contracts payable (1,576,000) (2,500,000) 0  
Proceeds from the exercise of stock options 430,000 731,000 1,543,000  
Repurchase and retirement of common shares 0 0 (20,000,000)  
Net cash used in financing activities (1,146,000) (6,565,000) (23,266,000)  
Net increase (decrease) in cash and cash equivalents 20,542,000 (47,212,000) 5,956,000  
Cash and cash equivalents, beginning of period 10,311,000 57,523,000 51,567,000 $ 51,567,000
Cash and cash equivalents, end of period 30,853,000 10,311,000 57,523,000 $ 10,311,000
Supplemental disclosures of cash flow information        
Income taxes paid 1,160,000 5,689,000 3,204,000  
Non-Cash Investing and Financing Activities        
Measurement period adjustments (See Note 2) 956,000 0 0  
Creation of contract liabilities from acquisition of subsidiaries 0 0 5,900,000  
Right of use assets capitalized $ 426,000 $ 212,000 $ 227,000